Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 20/20 | 0.58 |
| ▸ | IKZF3 | Q9UKT9 | 11/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 10/20 | 0.54 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
| ▸ | TNF | P01375 | 1/20 | 0.54 |
| ▸ | IL1B | P01584 | 1/20 | 0.54 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27099085 | 1.00 | CRBN (0.58) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL31747465 | 0.94 | CRBN (0.55) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL31753300 | 0.93 | CRBN (0.54) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL30936821 | 0.93 | CRBN (0.52) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL31752706 | 0.92 | CRBN (0.53) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL31129754 | 0.92 | CRBN (0.52) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL23250121 | 0.91 | CRBN (0.50) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL29874231 | 0.91 | CRBN (0.50) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL25034694 | 0.91 | CRBN (0.53) | CRBNIKZF3DDB1IKZF1BRD4 | |
| SCHEMBL19585510 | 0.90 | CRBN (0.54) | CRBNIKZF3DDB1IKZF1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114460-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2025-04-10 | — | — | US | disclosed |
| EP-4384520-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | Uppthera, Inc. (KR) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023017442-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023017446-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114460-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CRBN 2136/4885IKZF3 1904/4885DDB1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.